You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
格隆匯公吿精選(港股)︱恒瑞醫藥(01276.HK)旗下三款抗腫瘤藥物獲批臨牀試驗

【今日焦點】

恒瑞醫藥(01276.HK)旗下三款抗腫瘤藥物獲批臨牀試驗

恒瑞醫藥(01276.HK)發佈公吿,近日,公司及子公司蘇州盛迪亞生物醫藥有限公司、上海盛迪醫藥有限公司收到國家藥品監督管理局核准簽發關於注射用SHR-A1811、阿得貝利單抗注射液、蘋果酸法米替尼膠囊的《藥物臨牀試驗批准通知書》,將於近期開展臨牀試驗。

【重大事項】

佑駕創新(02431.HK)近日與長安汽車達成合作 獲得旗下新能源自主品牌的主力車型定點

阿爾法企業(00948.HK)收到法定要求償債書

江南布衣(03306.HK)擬新建一個集數字化研發、智能化倉儲運營於一體的現代化園區

【財報業績】

YGM TRADING(00375.HK)盈警:預期2025財年歸屬股東綜合虧損不超2500萬港元

【運營數據】

東風集團股份(00489.HK)1-5月累計汽車銷量672,780輛 同比下降約17.1%

綠城中國(03900.HK):前5月總合同銷售金額965億元

融創中國(01918.HK)5月實現合同銷售金額約48億元

弘陽地產(01996.HK):1–5月累計合約銷售金額為24.7億元

黛麗斯國際(00333.HK):第三財季銷售收入同比上升2.5%至3.05億港元

【醫藥創新】

恒瑞醫藥(01276.HK):枸櫞酸鈉血濾置換液獲准上市

山東新華製藥股份(00719.HK):取得注射用硫酸艾沙康唑藥品註冊證書

石藥集團(01093.HK):腺苷鈷胺膠囊獲藥品註冊批件

山東新華製藥股份(00719.HK):取得二十碳五烯酸乙酯軟膠囊藥品註冊證書

百奧賽圖-B(02315.HK)RenMab技術平台再獲日本專利授權,持續深化RenMice全人抗體╱TCR平台全球專利佈局

【收購出售】

金隅集團(02009.HK)斥33.64億元競得北京市一幅地塊

【股權激勵】

獅騰控股(02562.HK)授出869.2萬個受限制股份單位及55.66萬份購股權

藥明生物(02269.HK):授出合共6.41萬股受限制股份獎勵計劃受限制股份

【增發供股】

中國水業集團(01129.HK)擬折讓約8.43%配售最多5747萬股 籌資約1260萬港元

【回購註銷】

騰訊控股(00700.HK)6月5日耗資5.01億港元回購97.5萬股

友邦保險(01299.HK)6月5日耗資2.34億港元回購350萬股

阿里巴巴-W(09988.HK)6月4日耗資998萬美元回購67.1萬股

渣打集團(02888.HK)6月4日耗資887.4萬英鎊回購77.4萬股

貝殼-W(02423.HK)6月4日耗資500萬美元回購80.13萬股

匯豐控股(00005.HK)6月4日耗資9551.08萬港元回購102.96萬股

保誠(02378.HK)6月4日耗資222萬英鎊回購25.9萬股

海爾智家(06690.HK)6月5日耗資2476萬元回購100萬股A股

藥明康德(02359.HK)6月5日耗資2999.37萬元回購46.6萬股A股

石四藥集團(02005.HK)6月5日耗資1509.58萬港元回購540萬股

雍禾醫療(02279.HK)6月5日註銷4.7萬股購回股份

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account